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ABSTRACT
Tropical diseases are mainly found in the tropical regions of Asia, Africa and Latin 
America. They are a major Public Health problem in these regions, most of them are 
considered neglected diseases and remain as important contributors to the development 
of AKI (Acute Kidney Injury), which is associated with increased patients’ morbidity and 
mortality. In most countries, kidney disease associated to tropical diseases is attended at 
health services with poor infrastructure and inadequate preventive measures. The long‑term 
impacts of these infections on kidney tissue may be a main cause of future kidney disease 
in these patients. Therefore, the investigation of novel kidney injury biomarkers in these 
tropical diseases is of utmost importance to explain the mechanisms of kidney injury, 
to improve their diagnosis and prognosis, as well as the assessment to health systems 
by these patients. Since 2011, our group has been studying renal biomarkers in visceral 
and cutaneous leishmaniasis, schistosomiasis, leptospirosis and leprosy. This study has 
increased the knowledge on the pathophysiology of kidney disease in the presence of these 
infections and has contributed to the early diagnosis of kidney injury, pointing to glomerular, 
endothelial and inflammatory involvement as the main causes of the mechanisms leading 
to nephropathy and clinical complications. Future perspectives comprise establishing long‑
term cohort groups to assess the development of kidney disease and the patients’ survival, 
as well as the use of new biomarkers such as urinary exosomes to detect risk groups and 
to understand the progression of kidney injuries. 
KEYWORDS: Acute kidney injury. Biomarkers. Chronic kidney disease. Diagnosis. 
Hemodialysis. Neglected diseases. Neglected tropical diseases. 
INTRODUCTION
Tropical infections are important causes of morbidity and mortality and a major 
public health problem, especially in tropical regions of Asia, Africa and Latin 
America. Kidneys may be injured on several occasions, complicating the course of 
many infectious and parasitic diseases1. Several types of renal abnormalities have 
been observed in patients with tropical diseases, including visceral leishmaniasis 
(kala‑azar), dengue, leprosy, schistosomiasis, malaria and leptospirosis2.
Although several types of nephropathies are detected in tropical diseases in 
different clinical contexts, the diagnosis of renal dysfunction is almost always 
late, being an important cause of medical complications. Moreover, the long‑term 
impact of these infections on kidney tissues have never been investigated and may 
be a major cause of future kidney disease.
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Kidney injury mechanisms are not fully understood in 
many cases bringing major difficulties to specific therapeutic 
interventions. Worldwide, kidney injury identification is 
difficult, partly because of the low sensitivity of traditional 
diagnostic tests, such as serum creatinine measurement, 
being the condition often diagnosed only when the disease 
is fully established, with clear clinical signs and symptoms 
of renal dysfunction3.
Thus, it is of utmost importance to investigate 
new biomarkers that may be associated with the early 
identification of nephropathies observed in these infectious 
diseases. Many of these new renal biomarkers have been 
widely studied in the most common renal diseases but have 
been scarcely investigated in tropical diseases. Among them, 
the serum and urinary Neutrophil Gelatinase‑Associated 
Lipocalin (NGAL), urinary Monocyte chemotactic 
peptide‑1 (MCP‑1), urinary Vascular Endothelial Growth 
Factor (VEGF) and serum Fibroblast Growth Factor‑23 
(FGF‑23) are potential new renal biomarkers4‑7. These renal 
biomarkers can provide important information regarding the 
location and chronicity of the kidney injury, and the early 
and specific identification of injury mechanism8.
Moreover, due to the particular characteristics of tropical 
diseases, other variables have become of great importance, 
such as inflammatory mediators and endothelial biomarkers, 
which are involved in several glomerulopathies. Proteinuria, 
for instance, may be the result of the loss of the glomerular 
endothelial glycocalyx layer, which is rich in negatively 
charged proteoglycans9. The release of syndecan‑1 in plasma 
is a biomarker of endothelial glycocalyx injury that is present 
in these alterations10. Inflammatory mediators, such as 
interferon‑gamma (IFN‑γ), C‑reactive protein (CRP), and 
interleukins 6 and 17 (IL‑6; IL‑17) are associated with renal 
events in infectious diseases such as visceral leishmaniasis, 
dengue hemorrhagic fever and leprosy11,12. 
METHODS
This is a review of the literature on articles regarding 
kidney involvement in tropical diseases with focus on 
novel biomarkers of kidney injury, which are crucial for 
detecting this complication as early as possible. We have 
used the terms “acute kidney injury”, “kidney diseases”, 
“biomarkers”, “neglected diseases” and the following 
infections: leishmaniasis, leprosy, schistosomiasis, 
leptospirosis and dengue. PubMed was the database we 
have used to perform the search, and the study comprised 
the period 2010‑2019. We have also included the studies 
from our group to summarize the biomarkers we have 
investigated throughout the past years in the field of tropical 
infections.
RESULTS
Tropical diseases and kidney complications
Tropical infections continue to be an important cause 
of renal dysfunction, and some diseases show a significant 
frequency of acute kidney injury (AKI). It is likely that 
kidneys are particularly vulnerable to heat stress and to 
the re‑emergence of water‑ and vector‑borne infectious 
diseases. Examples include leptospirosis, leishmaniasis, 
leprosy, dengue, malaria and schistosomiasis. The 
contribution of AKI associated with infection in relation to 
other CKD factors has never been systematically evaluated. 
Research is needed to quantify the impact of infections on 
kidney health through prospective and cohort studies.
Dengue
Dengue is the most important mosquito‑borne viral 
disease that affects humans in the tropical and subtropical 
regions worldwide. The infection can be asymptomatic or 
severe and fatal manifesting as dengue hemorrhagic fever 
(DHF), which is characterized by hemorrhagic events, 
thrombocytopenia and shock2.
During DHF, viral antigens have already been detected 
in several organs, including the kidneys12. Most studies of 
renal involvement during dengue infection have reported 
considerable mortality rates, especially in DHF13. Glomerular 
biopsies show abnormalities such as hypertrophy and 
hyperplasia of mesangial and endothelial cells in some 
glomerular capillary lumens and focal thickening of the 
glomerular basement membrane. In other cases, immune 
complex deposition in the glomerulus is a common 
histological finding14. Vascular alterations have also been 
observed and seem to be related to the imbalance of the host’s 
immune response, as a consequence of the cytokines release 
profile and the type of cells present at the lesion sites15.
There are few studies on novel kidney injury biomarkers 
in dengue. Neutrophil gelatinase‑associated lipocalin 
(NGAL) and resistin, a molecule associated to inflammation 
were significantly more elevated in patients with dengue, 
in comparison with healthy subjects16.
Leishmaniasis
Visceral leishmaniasis (kala‑azar) is a chronic and lethal 
parasitic disease caused by intracellular parasites of the 
genus Leishmania. This is a zoonotic disease, typical of 
tropical areas, caused by Leishmania leishmania infantum 
chagasi, which is transmitted through a vector, an insect of 
the genus Lutzomyia17.
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Leishmania  causes intense parasitism of the 
reticuloendothelial system and can be found in the liver, 
spleen, bone marrow, lymph nodes, lungs, kidneys and 
intestine. As a consequence of the parasitism, the patient 
has accentuated anemia, leukopenia, thrombocytopenia and 
increased plasma gamma globulin levels2.
Renal involvement in chronic visceral leishmaniasis 
(VL) is often associated with the progression of infection 
and increased mortality in these patients. The development 
of AKI hinders the clinical management of patients with 
VL and is associated to increased length of hospital stay, 
poor prognosis and mortality11,18.
In one of the first studies on VL nephropathy, the presence 
of proteinuria < 1g/24h (57%), hematuria or leukocyturia 
(51%) were reported in 50 patients19. When performing 
the analysis of clinical findings due to renal dysfunction 
associated to VL in the literature, the following was 
observed: moderate proteinuria, hematuria, leukocyturia, 
microalbuminuria, hydroelectrolytic disorders such as 
hyponatremia, hypokalemia, hypochloremia, hypocalcemia, 
hypomagnesemia, increased excretion fraction of several 
electrolytes, and defects in urinary concentration and 
acidification19‑23. There is an induction of B‑cell humoral 
immune activity, which has been associated with glomerular 
disease in kala‑azar24. Consequently, antibodies produced 
in response to the infection may lead to immune complexes 
formation that deposit in the glomerulus and may induce a 
local inflammatory response, causing renal functional and 
structural abnormalities11.
Cutaneous leishmaniasis (CL) shows fewer renal 
alterations, as evidenced in the literature. The kidney injury 
mechanism that may occur also seems to be mediated by 
the deposition of immune complexes, formed after parasite 
destruction and formation of Donovan bodies. AKI occurs 
at a much lower frequency in CL when compared to VL, 
and seems to be more associated to the leishmanicidal 
treatment25. An important study of our group in 37 patients 
with CL observed changes in the glomerular filtration rate 
and, especially, tubular defects, including defects in urinary 
concentration and acidification, as well as changes in the 
fraction of sodium, potassium, calcium and phosphorus 
excretions25.
Leprosy
Leprosy is another infectious disease with chronic 
evolution that has affected humanity for millennia, and 
to this day remains a major public health problem in 
many countries worldwide. The disease is caused by 
Mycobacterium leprae, an acid‑fast bacillus, a mandatory 
intracellular microorganism that mainly affects the skin and 
peripheral nervous system, causing a wide variety of clinical 
and histopathological manifestations26. Depending on the 
degree and efficacy of cell‑mediated immunity, patients may 
present with a single, well‑delineated lesion (tuberculoid 
pole ‑ paucibacillary) or, at the other end , with many and 
poorly delineated lesions of several types, such as papules, 
nodules, and macules (virchowian pole –multibacillary)27. 
The disease is currently divided into four clinical forms, 
according to the World Health Organization (WHO) criteria: 
undetermined, tuberculoid, dimorphic and Virchowian28.
Renal lesions in patients with leprosy were initially 
studied in autopsies of infected patients. The rate of 
renal alterations can be as high as 72% in these patients, 
especially in the Virchowian form, which is the most severe 
form of the disease29. Although clinical renal complications 
are uncommon and usually mild when present, they may 
be silent, as they have never been investigated, constituting 
long‑term risk factors for the development of Chronic 
Kidney Disease in these patients30.
Only a few patients show a rapid decline in renal 
function or large proteinuria associated with edema. These 
uncommon cases were presented as case reports due to their 
rarity31. Glomerulonephritis seems to be the most common 
type of nephropathy in leprosy, accompanied by hematuria 
and increased proteinuria, especially in multibacillary 
forms32,33. The exact mechanism leading to the development 
of glomerulopathy is not completely understood. M. leprae 
does not seem to be directly involved, although it has 
already been found in the glomeruli of some patients32. The 
most common glomerular histological change is mesangial 
proliferative glomerulonephritis, which is often associated 
to immune complex depositions34.
Leptospirosis
Leptospirosis is a disease caused by a microorganism 
of the genus Leptospira. In total, nine pathogenic species 
are known, including L. interrogans35. The early phase of 
leptospirosis manifestations lasts three to seven days and 
includes fever, headaches, myalgia (especially in calves), 
nausea, vomiting, malaise and conjunctival hyperemia. 
Only 10% might progress to the second phase: Weil’s 
syndrome, which lasts from four to 30 days, showing more 
severe symptoms, such as jaundice, meningitis, pulmonary 
hemorrhage and acute kidney injury36.
The kidney is one of the main targets of Leptospira, 
and kidney injury can occur in 20‑85% of patients2. 
Clinical manifestations range from simple urinary 
sediment abnormalities to acute renal failure. Renal 
and glomerular tubular involvement may occur through 
several mechanisms, such as direct nephrotoxic action 
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of Leptospira, hemodynamic alterations and decreased 
glomerular filtration rate and rhabdomyolysis35. Loss of 
urinary electrolytes may lead to hypomagnesemia and 
hypokalemia and tubular alterations usually precede the 
decrease in the GFR. AKI in leptospirosis is often non‑
oliguric and hypokalemic. The etiopathology of AKI is 
complex and multifactorial, including the direct effect of 
the bacterium on renal tissues, hypovolemia, hypotension, 
rhabdomyolysis, hyperbilirubinemia and endothelial 
glycocalyx damage1,2. Novel biomarkers in leptospirosis 
have been investigated, including neutrophil gelatinase‑
associated lipocalin (NGAL), significantly associated to 
endothelial damage biomarkers (syndecan‑1 and ICAM‑1)9.
Malaria
Malaria is an important tropical disease, with great concern 
for Public Health, with most cases concentrated in Africa 
and in the Amazon forest region37‑39. Malaria is associated to 
disease in glomeruli, tubules and in the interstitial region39. 
AKI in malaria is more frequent in infections caused 
by Plasmodium falciparum, and manifestations include 
oliguria, severe metabolic acidosis, hypercatabolic state 
and hydroelectrolytic disorders, such as hyponatremia and 
hyperkalemia39. The histopathological findings in malaria‑
associated AKI include acute tubular necrosis, interstitial 
nephritis, inflammatory interstitial infiltrate, edema and 
glomerulonephritis, and the pathogenesis is associated to 
blockade of renal microcirculation, hemodynamic factors 
and hypovolemia40‑42. 
Malaria was one of the first parasitic diseases described 
to be a directly involved with glomerulonephritis39, and 
proteinuria is a frequent finding among infected patients, 
varying from 20 to 50% of cases43. Mesangial proliferation 
is the most frequent found pattern, with mild matrix 
expansion and deposits of eosinophilic material on the 
capillary walls in the mesangium and in Bowman’s capsule. 
Immunofluorescence shows granular deposits of IgM and 
C2 in the capillaries and mesangium40,44. Collapsing focal 
and segmental glomerulosclerosis is a less frequent lesion 
observed in malaria, with a non‑immune pattern45.
There are few studies investigating novel kidney injury 
biomarkers in malaria. Neutrophil gelatinase‑associated 
lipocalin (NGAL) and kidney injury molecule‑1 (KIM‑1) 
have been investigated in P. falciparum infections46. 
Another study found increased KIM‑1 and matrix 
metalloproteinase‑3 (MMP‑3) expression in tissues 
from autopsied patients with malaria‑associated AKI47. 
Chitinase‑3‑like 1 (CHI3L1), a glycoprotein that has been 
recently proposed as a urinary biomarker for AKI, was 
also associated to AKI in children with severe malaria, and 
evidenced its association with mortality48. Approximately 
31% of patients with malaria‑associated AKI had normal 
levels of creatinine at presentation, illustrating the 
importance of new AKI biomarkers39. 
Schistosomiasis
Schistosoma mansoni infection remains a major public 
health problem, affecting approximately 200 million 
people in more than 70 countries, mainly in Africa, Eastern 
Mediterranean and South America49. 
Renal involvement in schistosomiasis is mainly 
described by a glomerular involvement. Schistosomal 
glomerulopathy is associated to the hepatosplenic form 
of the disease, but it has also been observed in the 
hepatic intestinal form50. The immunological nature of 
the glomerular involvement in schistosomiasis is well 
established. The most frequently reported histological types 
are chronic membranoproliferative glomerulonephritis, 
segmental and focal glomerulosclerosis, usually associated 
to nephrotic syndromes51. Besides the parasites antigens, 
there are other important factors that seem to contribute to 
the pathogenesis of glomerular diseases in schistosomiasis, 
such as the collateral circulation of the portal system due to 
the degree of hepatic involvement, the inefficiency of the 
hepatic macrophage system, the severity and duration of the 
infestation and genetic factors52. Monocyte Chemotactic 
Protein‑1 (MCP‑1) has been investigated in chronic 
schistosomiasis caused by S. mansoni, and there is evidence 
of association to subclinical kidney disease, with significant 
association to albuminuria53.
The importance of early renal injury diagnosis
Until recently, there were over thirty definitions of AKI 
in the literature, rendering comparisons of results among 
studies very difficult. The absence of a universally accepted 
definition resulted in a huge variation in the described 
incidence of AKI, rendering comparisons between different 
studies and populations difficult8. In 2004, the ADQI (Acute 
Dialysis Quality Initiative) group proposed a consensual 
definition for AKI: the RIFLE (Risk, Injury, Failure, Loss 
and End‑stage Kidney Disease) classification. This is a 
classification system based on acute changes in serum 
creatinine measurements and/or variations in diuresis. It 
has three classes of severity (Risk, Injury and Failure) 
and two classes of evolution (loss and end‑stage kidney 
disease)54. In 2007, the Acute Kidney Injury Network 
(AKIN) classification was proposed, and revised this 
definition, suggesting minor changes based on the abrupt 
decrease in renal function (within 48 h) and establishing a 
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staging system in an attempt to define the degrees of renal 
dysfunction at the moment of diagnosis54,55.
More recently, the Kidney Disease Improving Global 
Outcomes (KDIGO) group has proposed a new definition 
including the increase in serum creatinine (0.3 mg/dL) 
during a 48‑h period, similar to the definition proposed 
by the AKIN group. In addition, a 50% increase in serum 
creatinine is considered within a seven days period, as 
suggested by the RIFLE criterion56.
However, the diagnosis of renal disease based on serum 
creatinine is still a late diagnosis, contributing to the high 
rates of AKI8. Clinical markers used to assess renal function, 
such as urinary volume and serum creatinine, are very 
limited due to extrarenal variables that interfere with their 
levels, and creatinine increases only occurs when half of 
the renal function is already impaired8,57.
Thus, the identification of kidney injury also becomes 
difficult due to the low sensitivity of diagnostic tests, being 
often diagnosed only when it is fully established, with 
evident clinical signs and symptoms. Early detection of 
patients at increased risk for acute renal dysfunction may 
be decisive for changing the clinical management and 
increasing patients’ survival, thus reducing the incidence 
of unfavorable outcomes58. As a result, there has been an 
exponential increase in studies with new AKI biomarkers 
that could be earlier and more specific markers of kidney 
injury59.
Novel kidney injury biomarkers
Studies on new kidney injury biomarkers aimed to 
obtain important information regarding the location 
of the kidney injury, assessing the injury intensity, the 
differential diagnosis of the injury, its predictive capacity 
of AKI in new or hospitalized patients and the impacts 
of therapeutic interventions. Several new biomarkers 
candidates are being studied in different clinical contexts, 
showing greater specificity and sensitivity in relation to 
classic clinical renal markers60. They can be quantified in 
serum and urine samples, showing relevant results in both 
cases. Urine is ideal for these diagnostic and prognostic 
studies, as it is a noninvasive and easily collected biological 
specimen whereas serum is also an important specimen, as 
its systemic biomarkers can influence urinary levels or even 
be associated with kidney disease61,62.
Each new biomarker has advantages and disadvantages, 
but they are usually more specific to a specific part of the 
nephron, helping to detect the site of kidney injury and 
elucidate the nephrotoxic mechanisms. The combined 
evaluation of several biomarkers in the same clinical 
context can complement the pathophysiological information 
of each one of the parameters and improve not only the 
understanding of the nephropathy but also its clinical 
diagnosis8,58,63.
For AKI, the most often studied biomarkers are 
Neutrophil Gelatinase‑Associated Lipocalin (NGAL), 
Kidney Injury Molecule‑1 (KIM‑1), FABP1 (Fatty Acid‑
Binding Protein 1) and FGF‑23 (fibroblast growth factor 23) 
(LEAF 2016). Other biomarkers are more specific for 
glomerulopathies8,63‑66. 
Use of new biomarkers in tropical diseases
Despite the increased risk of kidney disease and the 
infectious characteristic of tropical diseases, the use of new 
biomarkers for the detection and evaluation of prognosis 
in these patients has been scarce and has not followed 
the same pace as in other clinical contexts. In fact, this 
also characterizes these tropical diseases as neglected 
diseases for health services. Our group has been studying 
renal pathophysiology in these diseases and has evaluated 
different types of biomarkers over the past eight years, 
which could broaden the knowledge on the type of kidney 
injury, its early detection, risk groups for kidney disease and 
the mechanisms of kidney injury. Patients with cutaneous 
and visceral leishmaniasis, leptospirosis, schistosomiasis, 
and leprosy have already been studied. 
In 2011, renal tubular dysfunction was shown for the 
first time in patients with Cutaneous Leishmaniasis (CL), 
as well as the association with the altered expression of 
renal tubular transporters and compensatory mechanisms 
of these dysfunctions67. In this study, urinary exosomes 
were evaluated to elucidate the etiology of urinary 
concentration and acidification failure found in apparently 
asymptomatic patients67. It was observed that defects 
in urinary concentration were caused by a decrease in 
the expression of aquaporins (AQP2), accompanied by 
a compensatory increase of the NKCC2 transporter, 
responsible for sodium, potassium and chloride absorption 
into the interstitium, indicating problems of the AQP2 
production in the collecting duct (Figure 1). On the other 
hand, acidification defects were evidenced by the increase 
in the apical exchanger pendrin of β‑ intercalated cells in the 
cortical collecting duct. The pendrin secretes bicarbonate 
in the lumen and increases the urinary pH. Moreover, 
compensatory mechanisms have also been demonstrated 
due to the increase in the NHE3 exchanger, which secretes 
H+ ions in the lumen (Figure 1). However, the stratification 
of patients with these alterations and their long‑term impacts 
on renal function has not yet been studied.
Glomerular involvement is very present in infectious 
diseases such as VL, and can be decisive for the development 
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of AKI, contributing to the poor patient’s prognosis. The 
investigation and elucidation of the mechanisms involved 
in glomerular structural and functional alterations may also 
help in the discovery of new kidney injury biomarkers and 
new therapeutic targets for these glomerulopathies.
In 2014, in a prospective study, we showed high levels of 
urinary MCP‑1 and urinary oxidative stress in patients with 
visceral leishmaniasis who had normal serum creatinine, 
suggesting the presence of glomerular inflammation and 
incipient renal damage22. Another biomarker that seems 
to be reliable for the early detection of subclinical kidney 
injury in tropical diseases is NGAL, which had a good 
accuracy in a recent study from our group68.
Another study from our group showed early glomerular 
inflammation associated to increased proteinuria, 
albuminuria and renal oxidative stress in patients with 
leprosy, especially those with the virchowian form, 
suggesting that these patients had an increased risk of 
developing clinical kidney disease30.
A summary of the main tropical infections, the novel 
biomarkers that have been already investigated and their 
implications in clinical practice is shown in Table 1.
CONCLUSION
Tropical infections are currently one of the most 
worrying problems in Public Health, greatly impacting 
on the development of kidney diseases and their 
complications. Biomarkers aiming to the early detection 
of kidney injury are crucial to help decreasing the burden 
of kidney diseases, especially in the developing world, 
where tropical diseases are most common and access to 
healthcare is often difficult, including access to kidney 
diseases treatment. Hence, early detection of kidney 
Figure 1 - At the top: Plenty of (a) aquaporin (AQP2); (b) Na-K-2Cl cotransporter (NKCC2); (c) pendrin; (d) Na / H exchanger 
(NHE3). Adapted from Oliveira et al.67, with permission, ©2011 International Society of Nephrology / Elsevier. At the bottom of (b),(c) 
and (d): Western blotting analysis of the urinary exosome fraction, normalized according to the urinary creatinine, in controls and 
in patients with American cutaneous leishmaniasis.
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injury can prevent kidney disease progression, avoiding 
the need of expensive treatments such as dialysis and 
transplantation. It is possible that in the future, a “panel” of 
kidney injury biomarkers will be used in clinical practice, 
enabling the detection of any subclinical injury, from the 
glomeruli to any portion of the renal tubules.
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Table 1 - Tropical infections and novel biomarkers of acute kidney injury.
Infection Kidney involvement Novel biomarkers 
already investigated
Usefulness of the novel 
biomarkers
Dengue AKI NGAL, resistin
Higher among patients 
with dengue, evidence of 
inflammation.
Leishmaniasis
AKI, proteinuria, hematuria, 
leukocyturia, hydroelectrolytic 
disorders, defects in urinary 
concentration and acidification.
AQP2, NKCC2, NHE3 Detection of defects in tubular transport.
Leprosy Proteinuria, Glomerulonephritis, AKI/CKD. MCP-1
Association to AKI, 
multibacillary forms and 
oxidative stress.
Leptospirosis AKI NGAL, Syndecan-1, ICAM-1 AKI, Endothelial damage.
Malaria
AKI, Glomerulonephritis 
(mesangial proliferation, 
segmental and focal 
glomerulosclerosis)
NGAL, KIM-1, MMP-3, CHI3L1
Early detection of malaria-
associated AKI; Association to 
mortality.
Schistosomiasis
Glomerulonephritis 
(membranoproliferative 
glomerulonephritis, segmental 
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MCP-1
Association to subclinical 
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and albuminuria.
AQP2 = aquaporin 2; CHI3L1 = matrix metalloproteinase-3; NGAL = Neutrophil gelatinase-associated lipocalin; NKCC2 = Na-K-Cl 
co-transporter; KIM-1 = kidney injury molecule-1; MCP-1 = monocyte chemotactic protein-1; NHE3 = Na/H co-transporter.
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